Answers are grounded in this paper and cite their sources.
Demonstrates rapid duodenal mucosal recovery and symptom resolution following olmesartan discontinuation in an older male, highlighting drug-induced enteropathy as a celiac disease mimic.
An 85-year-old male patient presented for endoscopy due to chronic diarrhea passing four to six loose stools per day and weight loss of about 4 kg first noted 2 months before. Apart from chronic, H. pylori-positive pangastritis, the recent esophago-gastro-duodenoscopy (EGD) indicated subtle signs of mucosal atrophy in the duodenum with reduced villous structures, scalloping of folds and micro-nodularity as well as discrete fissuring with mosaic pattern (Figure 1a + b). A celiac disease biopsy protocol was pursued with four biopsies taken from the descending duodenum and two from the bulb, respectively. Pathologic assessment was consistent with Marsh IIIA stage, including subtotal villous atrophy with increased intraepithelial lymphocytosis >20/100 epithelial cells as supported by immunohistochemistry for CD3 and CD8 (Figure 1c + d). Of interest, pathology assessment of ileocolonic biopsies taken during a macroscopically unremarkable, same-session ileocolonoscopy likewise indicated lymphoplasmacellular infiltration and intraepithelial lymphocytosis >20/100 epithelial cells reminiscent of lymphocytic colitis, which is commonly associated with celiac disease. However, review of the patient's medication list revealed 40-mg olmesartan intake per day since >3 years, which was immediately stopped. Celiac disease serology (anti-transglutaminase and anti-endomysium IgA) remained negative. The patient's symptoms improved rapidly with normalization of stool habits within 3 days without need for anti-inflammatory medication. Repeat upper endoscopy and duodenal histology 4 weeks later showed complete resolution of macroscopic and microscopic findings in the duodenum (Figure 2a–d). Olmesartan-associated enteropathy has been first described in a subset of presumably seronegative celiac disease individuals. Albeit its distinct mechanism is yet to be better characterized, olmesartan-associated enteropathy is considered to relate to cell-mediated immune damage and inhibitory effects of GI-expressed angiotensin II receptors (compare also recent COVID-19 discussion) on transforming growth factor-β (TGF-β), potentially disbalancing cellular gut hemostasis. Taken together, to avoid undue clinical decisions, clinicians and/or endoscopists should remember olmesartan (or other ARB)-induced enteropathy with or without colonic involvement as an important celiac disease mimic with rapid and durable remission after stopping the drug.
No takes yet. Share an insight, caveat, or question.
Zimmer et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: